Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Dordaviprone + Navitoclax |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Dordaviprone | Modeyso | TIC-10|TIC10|ONC201 | Akt Inhibitor (Pan) 22 ERK Inhibitor (pan) 21 | Modeyso (dordaviprone) is a small molecule dopamine receptor D2 (DRD2) antagonist (PMID: 31702782) that induces TRAIL signaling (PMID: 23390247) and activates the mitochondrial protease, ClpP (PMID: 31021596), leading to anti-tumor activity (PMID: 31456142, PMID: 31702782). Modeyso (dordaviprone) is FDA-approved for use in adult and pediatric patients 1 year and older with diffuse midline glioma harboring an H3 K27M mutation who progressed on prior therapies (FDA.gov). |
| Navitoclax | ABT-263 | BCL-XL inhibitor 14 BCL2 inhibitor 29 | Navitoclax (ABT-263) is a BCL2, BCL-XL, and BCL-W inhibitor, which may enhance the efficacy of chemotherapeutics (PMID: 25787766, PMID: 32513939). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PTEN mut TP53 mut | glioblastoma | sensitive | Dordaviprone + Navitoclax | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Modeyso (dordaviprone) and Navitoclax (ABT-263) increased apoptosis and worked synergistically to inhibit proliferation of a glioblastoma cell line harboring mutations in PTEN and TP53 in culture (PMID: 26474387). | 26474387 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|